Autoimmune CAR T cell development faces hurdles

Progress in autoimmune CAR T cell therapies is slowing the development of affordable treatments for millions

The source describes how progress in autoimmune CAR T cell therapies is slowing the development of affordable treatments for millions. This friction occurs within the health sector, where the complexity of these therapies creates barriers to cost-effective solutions for conditions like rheumatoid arthritis and lupus.

This delay represents a critical constraint on access to life-saving treatments for millions who lack affordable options. When high-cost therapies stall development, it traps patients in a cycle where medical needs remain unmet despite technological advances. The friction here directly impacts the care sector’s ability to deliver equitable treatment access.

The source provides no additional detail beyond this friction point. A reader must consult the original reporting to understand the specific mechanisms or timelines involved.

Source: Nature Medicine